HUDSON, N.H., Aug. 30 /PRNewswire/ -- Atrium Medical Corporation announced today that it has received U.S. FDA 510K marketing clearance for a new vascular implant device called the iVENA(TM) Vascular Patch. Indicated for use in the surgical repair and closure of the vascular system, Atrium’s latest implant technology is an extremely thin, reinforced biomaterial that suggests unsurpassed surgical installation convenience, reduced blood loss and handling efficiency. The iVENA(TM) Vascular Patch provides today’s discriminating vascular surgeon with an easy-to-use alternative to conventional implantable vascular repair materials. This new product utilizes a proprietary composite film lamination process that is also used in Atrium’s most advanced vascular graft products called FLIXENE(TM). The all new iVENA Vascular Patch offers physicians an extremely thin and flexible composite material that exhibits superior needle hole strength and anastomotic suture line integrity. It will be made in a wide variety of shapes and sizes to accommodate surgical interventions of the vascular system, and it is expected to become commercially available in the first quarter of 2007. Atrium’s iVENA(TM) Vascular Patch technology is the latest advance in a series of unique biotechnology innovations, built upon 2 decades of excellence in Cardiovascular implant and biomaterial science. This late breaking med-tech product is also part of the company’s evolving drug eluting and coating developments, currently in preclinical research.
About Atrium
Atrium Medical Corporation of Hudson, New Hampshire, celebrating 25 years of US based healthcare innovation manufactures over two million sterile medical devices each year which are distributed worldwide. Atrium’s vast expertise in developing medical device technologies for the treatment of cardiovascular disease has brought a number of breakthrough advances in several diversified healthcare markets including interventional cardiology, chest trauma care and thoracic drainage, vascular surgery, hernia and soft tissue repair. Maintaining a commitment to the latest ISO 13485 Quality Standards, state-of-the-art manufacturing and automation, cell biology and biomaterial discovery programs, Atrium continues to excel in several specialty healthcare markets requiring surgical intervention. For more information call 800-370-7899 or visit Atrium’s website http://www.atriummed.com
Atrium Medical Corporation
CONTACT: Kelly MacMillan, Marketing Communications Manager for AtriumMedical Corporation, +1-603-880-1433 ext. 5209, +1-603-880-4545 (fax),kmacmillan@atriummed.com
Web site: http://www.atriummed.com/
